[{"orgOrder":0,"company":"OncoGenerix USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Peptide vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"OncoGenerix USA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"OncoGenerix USA \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OncoGenerix USA \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by OncoGenerix USA

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BMWS24
                          Not Confirmed
                          BMWS24
                          Not Confirmed

                          Details : OncoGen researchers propose a novel approach for producing epitope-based peptide vaccine candidates for the novel China coronavirus (nCoV).

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 28, 2020

                          Lead Product(s) : Peptide vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank